Literature DB >> 22144419

Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.

Dimitrios Panidis1, Konstantinos Tziomalos, Georgios Misichronis, Efstathios Papadakis, George Betsas, Ilias Katsikis, Djuro Macut.   

Abstract

BACKGROUND: Polycystic ovary syndrome (PCOS) is a heterogeneous disorder characterized by oligo- or anovulation (ANOV), biochemical or clinical manifestations of hyperandrogenemia (HA) and PCOs. Four phenotypes of PCOS exist [phenotype 1 (ANOV + HA + PCO), phenotype 2 (ANOV + HA), phenotype 3 (HA + PCO) and phenotype 4 (ANOV + PCO)] but the differences between them are not well studied. We compared markers of insulin resistance (IR) and endocrine characteristics between the different PCOS phenotypes.
METHODS: We prospectively studied 1212 consecutive women with PCOS and 254 BMI-matched healthy women.
RESULTS: Phenotypes 1-4 were present in 48.2, 30.7, 9.7 and 11.4% of patients, respectively. BMI did not differ between the four phenotypes and controls. Both normal weight and overweight/obese women with phenotypes 1 and 2 were more insulin resistant than controls. Overweight/obese, but not normal weight, women with phenotype 4 were more insulin resistant than controls, while IR in women with phenotype 3 did not differ from controls regardless of obesity. In normal weight subjects, women with phenotypes 1 and 2 were more insulin resistant than women with phenotype 4. In overweight/obese subjects, women with phenotype 1 were more insulin resistant than women with phenotypes 2 and 3 and women with phenotype 4 were more insulin resistant than those with phenotype 3. Circulating androgens were higher in normal weight and overweight/obese PCOS patients with phenotypes 1-3 compared with those with phenotype 4, and higher in normal weight PCOS patients with phenotype 1 than in those with phenotype 2.
CONCLUSIONS: Phenotype 1 is associated with more IR and more pronounced HA than phenotype 2. Phenotypes 2 and 4 with obesity, are also characterized by IR. In contrast, phenotype 3 is not associated with IR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22144419     DOI: 10.1093/humrep/der418

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  29 in total

1.  Impact of hormonal contraception and weight loss on high-density lipoprotein cholesterol efflux and lipoprotein particles in women with polycystic ovary syndrome.

Authors:  Anuja Dokras; Martin Playford; Penny M Kris-Etherton; Allen R Kunselman; Christy M Stetter; Nancy I Williams; Carol L Gnatuk; Stephanie J Estes; David B Sarwer; Kelly C Allison; Christos Coutifaris; Nehal Mehta; Richard S Legro
Journal:  Clin Endocrinol (Oxf)       Date:  2017-03-09       Impact factor: 3.478

2.  Polycystic ovary syndrome: what's in a name?

Authors:  Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2014-02-03       Impact factor: 5.958

3.  Metabolic implications of menstrual cycle length in non-hyperandrogenic women with polycystic ovarian morphology.

Authors:  Miro Šimun Alebić; Nataša Stojanović; Dinka Pavičić Baldani; Lea Smirčić Duvnjak
Journal:  Endocrine       Date:  2016-08-03       Impact factor: 3.633

4.  Impact of hypocaloric dietary intervention on ovulation in obese women with PCOS.

Authors:  Brittany Y Jarrett; Marla E Lujan
Journal:  Reproduction       Date:  2016-10-31       Impact factor: 3.906

Review 5.  Cardiometabolic aspects of the polycystic ovary syndrome.

Authors:  Harpal S Randeva; Bee K Tan; Martin O Weickert; Konstantinos Lois; John E Nestler; Naveed Sattar; Hendrik Lehnert
Journal:  Endocr Rev       Date:  2012-07-24       Impact factor: 19.871

Review 6.  Cardiometabolic Features of Polycystic Ovary Syndrome: Role of Androgens.

Authors:  Licy L Yanes Cardozo; Damian G Romero; Jane F Reckelhoff
Journal:  Physiology (Bethesda)       Date:  2017-09

7.  Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Self-reporting Features of Polycystic Ovary Syndrome.

Authors:  Nina M Clark; Amanda J Podolski; Eric D Brooks; Donna R Chizen; Roger A Pierson; Denis C Lehotay; Marla E Lujan
Journal:  Reprod Sci       Date:  2014-02-11       Impact factor: 3.060

Review 8.  Obesity and PCOS: implications for diagnosis and treatment.

Authors:  Richard S Legro
Journal:  Semin Reprod Med       Date:  2012-10-16       Impact factor: 1.303

9.  Comparing classic and newer phenotypes in Greek PCOS women: the prevalence of metabolic syndrome and their association with insulin resistance.

Authors:  V Vaggopoulos; E Trakakis; C Chrelias; P Panagopoulos; G Basios; S Makridima; V D Sioulas; G Simeonides; G Labos; E Boutati; D Kassanos
Journal:  J Endocrinol Invest       Date:  2012-11-27       Impact factor: 4.256

10.  Endocrine and Metabolic Profile of Different Phenotypes of Polycystic Ovarian Syndrome.

Authors:  Saxena Pikee; Singh Shivani; Bhattacharjee Jayshree
Journal:  J Obstet Gynaecol India       Date:  2016-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.